Executive Summary
The 9 proxy filings reveal a mixed landscape for the 2026 annual meeting season, with several high-risk special situations demanding immediate attention. Laser Photonics and Arogo Capital are in critical financing and survival phases, with special meetings on June 26th that could determine their futures, while Entera Bio shows volatile stock performance and a net loss.
Period-over-period data highlights Laser Photonics' impressive 144% YoY revenue growth to $8.3M, but this is overshadowed by ongoing operational losses and reliance on dilutive warrant financing. Arogo Capital's trust account redemption price of ~$11.53 per share significantly exceeds its market price of $8.50, creating a clear arbitrage opportunity but also signaling a likely liquidation if the extension is not approved. BioAtla's 50-for-1 reverse stock split signals a distressed equity story, while Health Catalyst's proposal to declassify the board represents a positive governance shift. Overall, the filings point to a bifurcated market where a few companies are executing well, but several are facing existential challenges, creating both high-risk and high-reward opportunities for active investors.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: DEF 14A
Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from May 27, 2026.
Investment Signals (9)
-
Revenue surged 144% YoY to $8.3M (from $3.4M), driven by laser blasting technology targeting government and Fortune 1000 clients. However, the company continues to rely on warrant inducement financing, raising dilution concerns. [BULLISH on revenue growth, BEARISH on financing structure]
-
Trust account redemption price of ~$11.53 per share vs. market price of $8.50 (as of June 2, 2026), presenting a ~35% arbitrage opportunity for shareholders who redeem. The extension vote on June 26 is critical; failure to approve likely leads to liquidation. [BULLISH for arbitrageurs, BEARISH for equity holders]
-
Stock price volatility is extreme: $0.60 (2023) -> $2.28 (2024) -> $1.94 (2025), a 280% rise followed by a 15% decline. The company continues to report net losses, and no dividends have been paid. [BEARISH on profitability and stability]
-
Proposal to declassify the board is a positive governance signal, potentially increasing board accountability and aligning with shareholder interests. This could attract ESG-focused investors. [BULLISH on governance]
-
The amendment and restatement of the 2018 Long Term Incentive Plan suggests a focus on retaining and incentivizing key talent, which could be positive for long-term performance. [BULLISH on talent retention]
-
The 50-for-1 reverse stock split (effective April 6, 2026) is a classic distress signal, often used to maintain listing requirements. This typically indicates underlying financial weakness and can lead to further dilution. [BEARISH on equity value]
- Advanced Drainage Systems ↓ (NEUTRAL)▲
The company is holding a virtual-only annual meeting, which is a growing trend but can reduce shareholder engagement. The lack of any shareholder proposals or governance changes suggests a stable, low-event situation.
-
Several directors and the Estate of Joseph Feldschuh each beneficially own over $100,000 in stock, indicating significant insider alignment with shareholders. [BULLISH on insider alignment]
-
The board met only four times during the fiscal year, which is low for a public company. This could indicate a lack of active oversight, especially given the company's small size and need for strategic direction. [BEARISH on board engagement]
Risk Flags (8)
- Arogo Capital/Liquidation Risk↓ [HIGH RISK]▼
The sponsor has indicated it will not fund the required deposit under the current charter, making the extension vote on June 26 critical. If the extension is not approved, the company will liquidate, and shareholders will receive the trust value.
- Laser Photonics/Dilution Risk↓ [HIGH RISK]▼
The company is seeking approval for two warrant inducement agreements (March and April) that have already generated $5.48M in gross proceeds. This reliance on dilutive financing to fund operations is unsustainable and signals ongoing cash burn.
- BioAtla/Reverse Split Risk↓ [HIGH RISK]▼
The 50-for-1 reverse stock split is a red flag for financial distress. Post-split, the company has only 1,659,554 shares outstanding, making it highly susceptible to volatility and potential delisting if the stock price falls again.
- Entera Bio/Profitability Risk↓ [HIGH RISK]▼
The company reported a net loss (specific figures not provided) and has not paid dividends. Combined with a declining stock price from $2.28 to $1.94, this signals a lack of a clear path to profitability.
- Amesite Inc./Board Engagement Risk↓ [MEDIUM RISK]▼
The board met only four times in the fiscal year. For a small, early-stage company, this level of board activity may be insufficient for effective governance and strategic oversight.
- Laser Photonics/Governance Risk↓ [MEDIUM RISK]▼
The special meeting is being held to approve financing agreements that are already in place, suggesting a potential lack of shareholder oversight in the decision-making process.
- Arogo Capital/Market Price Dislocation↓ [HIGH RISK]▼
The market price ($8.50) is significantly below the trust redemption price ($11.53), indicating that the market is pricing in a high probability of liquidation or a failed business combination.
- Daxor Corp/Concentrated Ownership↓ [MEDIUM RISK]▼
The Estate of Joseph Feldschuh and several directors hold significant beneficial ownership, which could lead to governance issues or decisions that favor insiders over minority shareholders.
Opportunities (8)
- Arogo Capital/Arbitrage Opportunity↓ (OPPORTUNITY)◆
Shareholders can redeem their shares for ~$11.53, a 35% premium over the current market price of $8.50. The redemption deadline is June 23, 2026, providing a clear, time-sensitive arbitrage for holders.
- Laser Photonics/Revenue Growth Story↓ (OPPORTUNITY)◆
The 144% YoY revenue growth to $8.3M is impressive and driven by a differentiated laser blasting technology. If the company can achieve profitability, the current valuation could be attractive.
- Health Catalyst/Governance Improvement↓ (OPPORTUNITY)◆
The proposal to declassify the board is a positive step that could lead to improved shareholder returns and attract long-term institutional investors.
- Cirrus Logic/Talent Incentive↓ (OPPORTUNITY)◆
The amended 2018 Long Term Incentive Plan could drive strong performance if it aligns executive compensation with shareholder value creation.
- Advanced Drainage Systems/Stable Dividend↓ (OPPORTUNITY)◆
While not explicitly mentioned, the company's stable profile and lack of drama suggest it could be a reliable dividend payer or buyback candidate, appealing to income-focused investors.
- Entera Bio/Turnaround Potential↓ (OPPORTUNITY)◆
The stock price has corrected from its 2024 high of $2.28 to $1.94. If the company can provide a clear path to profitability or positive clinical data, the current price could represent a buying opportunity.
- BioAtla/Post-Split Valuation↓ (OPPORTUNITY)◆
After the 50-for-1 reverse split, the stock may be undervalued if the company's pipeline or cash position is stronger than perceived.
- Daxor Corp/Insider Alignment↓ (OPPORTUNITY)◆
With directors and the Estate of Joseph Feldschuh holding significant stakes, there is strong insider alignment with shareholders, which can lead to better capital allocation decisions.
Sector Themes (6)
- Special Purpose Acquisition Company (SPAC) Distress◆
Arogo Capital's filing highlights the ongoing challenges in the SPAC market, with sponsors unable to fund extensions and companies facing liquidation. This theme is likely to persist as the 2022 vintage of SPACs reaches their deadlines.
- Reliance on Dilutive Financing◆
Laser Photonics and BioAtla both demonstrate a reliance on dilutive financing (warrant inducements and reverse splits) to stay afloat. This is a common theme among micro-cap companies with high cash burn rates.
- Virtual-Only Meetings Becoming Standard◆
Advanced Drainage Systems, Cirrus Logic, Health Catalyst, Laser Photonics, Arogo Capital, Amesite, and BioAtla are all holding virtual-only meetings. This trend reduces shareholder engagement and can be a red flag for governance activists.
- Governance Improvements as a Catalyst◆
Health Catalyst's proposal to declassify the board is a positive governance move. This theme of board declassification and increased shareholder rights is gaining traction and can be a catalyst for stock appreciation.
- Biotech Volatility and Cash Burn◆
Entera Bio and BioAtla both show the classic biotech pattern of high volatility, net losses, and reliance on financing. Investors in this sector must be prepared for significant dilution and price swings.
- Insider Alignment in Small Caps◆
Daxor Corp's significant insider ownership is a positive signal. In small-cap companies, high insider ownership is often correlated with better long-term performance and alignment with minority shareholders.
Watch List (8)
- Arogo Capital/Special Meeting↓ (HIGH PRIORITY)👁
The vote on the extension to June 29, 2028, is on June 26, 2026. The redemption deadline is June 23. Watch for the outcome and any last-minute deal announcements.
- Laser Photonics/Special Meeting↓ (HIGH PRIORITY)👁
The vote on warrant inducement agreements is on June 26, 2026. Watch for shareholder approval and any subsequent dilution or financing updates.
- BioAtla/Annual Meeting↓ (MEDIUM PRIORITY)👁
The meeting is on July 16, 2026. Watch for any updates on the company's pipeline or financial position following the reverse split.
- Health Catalyst/Annual Meeting↓ (MEDIUM PRIORITY)👁
The meeting is on July 16, 2026. Watch for the outcome of the board declassification proposal, which could be a catalyst.
- Entera Bio/Annual Meeting↓ (MEDIUM PRIORITY)👁
The meeting date is not specified, but watch for any updates on profitability or clinical milestones that could reverse the stock's decline.
- Amesite Inc./Annual Meeting↓ (LOW PRIORITY)👁
The meeting is on July 13, 2026. Watch for any financial disclosures or strategic updates, given the low board meeting frequency.
- Cirrus Logic/Annual Meeting↓ (LOW PRIORITY)👁
The meeting is on July 31, 2026. Watch for the outcome of the LTIP amendment vote, which could signal future compensation strategy.
- Advanced Drainage Systems/Annual Meeting↓ (LOW PRIORITY)👁
The meeting is on July 16, 2026. While low-risk, watch for any unexpected shareholder proposals or governance changes.
Filing Analyses
(9)
03-06-2026
Advanced Drainage Systems, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, to be held via webcast on July 16, 2026. The filing includes proposals to elect nine directors, ratify the appointment of Deloitte & Touche LLP as independent auditor for fiscal year 2027, and hold a non-binding advisory vote on executive compensation. The company reported having 76,645,382 shares of common stock outstanding as of the May 22, 2026 record date.
- · The Annual Meeting will be held via live webcast only at www.virtualshareholdermeeting.com/WMS2026 on July 16, 2026 at 10:00 a.m. Eastern Time.
- · Stockholders of record as of May 22, 2026 are entitled to vote; each share of common stock carries one vote, and cumulative voting is not permitted.
- · The proxy materials were first sent to stockholders on or about June 3, 2026.
- · The company's fiscal year 2026 ended March 31, 2026.
- · The proxy statement includes a Compensation Discussion and Analysis section and a Pay-Versus-Performance table covering fiscal years 2021–2026.
- · The Audit Committee report and information on director compensation and stock ownership policies are included.
03-06-2026
Cirrus Logic, Inc. filed its definitive proxy statement (DEF 14A) on June 3, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on July 31, 2026. The meeting will include votes on the election of seven director nominees, ratification of Ernst & Young LLP as independent auditor, an advisory vote on named executive officer compensation, and approval of an amendment and restatement of the 2018 Long Term Incentive Plan. As of the record date of June 1, 2026, there were 50,452,718 shares of common stock outstanding.
- · The annual meeting will be held virtually on July 31, 2026, at 11:00 a.m. Central Time via live webcast at www.virtualshareholdermeeting.com/CRUS2026.
- · Stockholders of record as of June 1, 2026, are entitled to vote.
- · Proposals include: election of seven directors, ratification of Ernst & Young LLP as independent auditor for fiscal year ending March 27, 2027, advisory vote on named executive officer compensation, and approval of an amendment and restatement of the 2018 Long Term Incentive Plan.
- · The proxy materials were made available beginning June 3, 2026.
03-06-2026
Daxor Corporation filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders to be held on June 23, 2026. The meeting will include the election of six directors and ratification of Bush & Associates, CPA as the independent auditor. The Board recommends voting 'FOR ALL NOMINEES' and 'FOR' ratification. As of the record date (May 20, 2026), the company had 5,838,224 shares outstanding, with several directors and the Estate of Joseph Feldschuh each beneficially owning over $100,000 in stock, while other directors hold smaller positions.
- · The annual meeting will be held at the Nasdaq Stock Exchange offices, 4 Times Square, New York, NY on June 23, 2026 at 10:30 AM EDT.
- · The proxy statement was mailed on or about May 29, 2026.
- · Stockholders of record as of May 20, 2026 are entitled to vote; each share entitles one vote.
- · A quorum requires a majority of outstanding shares (over 2,919,112 shares) present in person or by proxy.
- · The Board currently has no standing compensation or nominating committees but is in the process of implementing them.
- · Stockholder nominations for the 2027 annual meeting must be submitted by February 6, 2027.
- · Michael Feldschuh and Jonathan Feldschuh are brothers and are classified as 'interested persons' due to their employment with the company.
- · The company is not subject to all Nasdaq corporate governance rules, which may affect protections for minority stockholders.
03-06-2026
Health Catalyst filed a DEF 14A proxy statement for its 2026 Annual Meeting to be held virtually on July 16, 2026. Stockholders will vote on electing two Class I directors, ratifying Ernst & Young as auditor, approving executive compensation on an advisory basis, and declassifying the board. The record date is May 22, 2026, with 73,894,020 shares outstanding.
- · Annual Meeting will be held virtually on July 16, 2026 at 3:00 p.m. ET.
- · Stockholders of record as of May 22, 2026 are entitled to vote.
- · Proposals include election of two Class I directors, ratification of auditor, advisory vote on executive compensation, and declassification of the board.
- · Board recommends FOR all proposals.
- · Plurality voting for directors; majority of votes cast for other proposals.
03-06-2026
Laser Photonics Corp is holding a Special Meeting of Shareholders on June 26, 2026, to vote on two proposals: approval of the March Warrant Inducement Agreement and the April Warrant Inducement Agreement, which have generated gross proceeds of $1,483,520.40 and $4,000,559.50 respectively. The company reported strong revenue growth of 144% YoY to $8.3 million for fiscal 2025, up from $3.4 million in 2024, driven by its laser blasting technology targeting government, Fortune 1000, and small/medium business segments. However, the company continues to rely on warrant inducement financing and has not disclosed profitability metrics, indicating ongoing operational losses.
- · Special Meeting will be held virtually on June 26, 2026 at 12:00 PM ET.
- · Record Date for voting is May 13, 2026; 38,568,263 shares of Common Stock outstanding.
- · Board recommends voting FOR both Proposal 1 (March Warrant Inducement Agreement) and Proposal 2 (April Warrant Inducement Agreement).
- · The March Warrant Inducement Agreement involves Series A-3 and A-4 warrants with an exercise price of $1.08 per share.
- · The April Warrant Inducement Agreement involves Series A-5 and A-6 warrants with an exercise price of $0.975 per share.
- · Company entered a license agreement with Fonon Drone Shield Solutions on May 21, 2024, issuing 3,000,000 restricted shares for exclusive worldwide license to laser material processing technology.
- · Company initiated sales efforts in December 2019.
- · Quorum requires at least one-third of outstanding shares present in person or by proxy.
03-06-2026
Arogo Capital Acquisition Corp. filed a definitive proxy statement (DEF 14A) for a special meeting on June 26, 2026, seeking stockholder approval to extend the deadline to complete a business combination from June 29, 2026 to June 29, 2028, and to amend the charter to allow stockholder action by written consent. The sponsor has indicated it will not fund the required deposit under the current charter, making the extension critical to avoid liquidation; however, the trust account redemption price of ~$11.53 per share significantly exceeds the recent market price of $8.50, and the company faces a material risk of failing to complete a business combination by the original deadline.
- · The special meeting will be held virtually on June 26, 2026 at 9 a.m. Eastern Time.
- · The redemption deadline for stockholders is 5:00 p.m. Eastern Time on June 23, 2026.
- · The trust account redemption price is approximately $11.53 per share, while the OTC closing price on June 2, 2026 was $8.50.
- · The sponsor, officers and directors collectively own 2,587,500 founder shares and 466,150 private placement units.
- · If the extension is not approved and no business combination is completed by June 29, 2026, the company will redeem public shares and dissolve.
- · The charter currently requires net tangible assets of at least $5,000,001 to complete a business combination; the company believes this limitation is unnecessary.
03-06-2026
Amesite Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on July 13, 2026. The board proposes the re-election of directors Ann Marie Sastry and Barbie Brewer for three-year terms, ratification of the independent registered public accounting firm, an amendment to the 2018 Equity Incentive Plan, and approval of warrant exercises. The filing notes that the board met four times during the fiscal year ended June 30, 2025, with all members attending at least 75% of board and committee meetings, but does not disclose any financial results or performance metrics.
- · The Annual Meeting will be held virtually on July 13, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/AMST2026.
- · Stockholders of record as of May 22, 2026 are entitled to vote.
- · The board is classified into three classes; Class II directors (Sastry and Brewer) are up for election for a three-year term.
- · Directors may be removed only for cause by a 66 2/3% supermajority vote.
- · Four of five current directors attended last year's Annual Meeting.
- · The proxy materials are available at www.proxyvote.com.
03-06-2026
BioAtla, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on July 16, 2026. The meeting will include the election of Class III directors Jay M. Short, Ph.D. and Edward Williams, ratification of Ernst & Young LLP as independent auditor for FY2026, and a non-binding advisory vote on executive compensation. The company effected a 50-for-1 share consolidation on April 6, 2026, reducing outstanding shares to 1,659,554 as of the May 18, 2026 record date.
- · The 2026 Annual Meeting will be held virtually on July 16, 2026 at 8:00 a.m. Pacific Time.
- · A 50-for-1 share consolidation was effected on April 6, 2026, with all share and per share amounts retroactively adjusted.
- · Stockholders of record as of May 18, 2026 are entitled to vote; 1,659,554 shares outstanding.
- · The board recommends voting FOR all three proposals: election of directors, ratification of Ernst & Young, and advisory vote on executive compensation.
- · No stockholder proposals were received for the meeting.
03-06-2026
Entera Bio Ltd. filed a DEF 14A proxy statement for its 2026 Annual Meeting, disclosing executive compensation, director nominees, and stock performance. Stock prices were $0.60 (2023), $2.28 (2024), and $1.94 (2025), reflecting a sharp rise followed by a decline. The company reported a net loss, but specific figures were not provided in this excerpt. Executive officers include CEO Miranda Toledano and CFO Dana Yaacov-Garbeli, while director nominees include Sean Ellis, Geno J. Germano, and Steven D. Rubin.
- · Non-PEO NEOs for 2024 were Hillel Galitzer and Dana Yaacov-Garbeli; for 2025 were Hillel Galitzer and Gregory Burshtein.
- · Cumulative TSR calculation assumes $100 invested on December 31, 2023, but no TSR value is provided.
- · No dividends were paid on share or option awards for all periods presented.
- · The Board has three classes with staggered three-year terms; Class III directors' term expires at this meeting.
- · Three director nominees are proposed for election: Sean Ellis, Geno J. Germano, and Steven D. Rubin.
Get daily alerts with 9 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 9 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Executive Compensation Proxy SEC Filings
🇺🇸 More from United States
View all →May 28, 2026
US Pre-Market SEC Filings Roundup — May 28, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Nasdaq 100 Stocks SEC Filings — May 27, 2026
Nasdaq 100 Stocks SEC Filings